Feb 11, 2019 - Overpriced toxic stocks are generally susceptible to external shocks and loaded with huge amount of debt.
Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
Jan 25, 2019 - Overhyped toxic stocks are usually susceptible to external shocks and loaded with huge amount of debt.
Jan 24, 2019 - Gabelli & Co issues rating change for INCY
Jan 23, 2019 - A low key week for the biotech sector with regular drug approvals and pipeline updates.
Jan 14, 2019 - Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
Jan 08, 2019 - We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
Jan 04, 2019 - Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
Dec 21, 2018 - FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.
Dec 19, 2018 - A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.